ORIGINAL PAPER
Can stanniocalcin-2 be regarded as a novel non-invasive
biomarker of advanced liver steatosis in obese children?
A preliminary study
1
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology, Medical University of Białystok, Białystok, Poland
Submission date: 2022-05-13
Final revision date: 2022-06-09
Acceptance date: 2022-06-10
Publication date: 2022-12-30
Pediatr Pol 2022;97(4):302-307
KEYWORDS
TOPICS
ABSTRACT
Introduction:
With the increasing prevalence of liver steatosis, non-invasive methods are sought to detect it and to assess the degree of lipid accumulation in the liver. The aim of this preliminary study was to assess the serum concentrations of stanniocalcin-2 (STC-2), pregnancy-associated plasma protein A (PAPP-A) and insulin-like growth factor binding protein (IGFBP-4) among children with obesity, check if they detect liver steatosis and determine whether they differentiate mild and advanced steatosis.
Material and methods:
This prospective study involved 62 obese children (39 boys and 23 girls, median age 13.75 years). Infectious, autoimmune, metabolic and toxic liver conditions were excluded. All subjects underwent body composition analysis, anthropometric measurements, abdominal ultrasound and routine blood chemistry analyses. STC-2, PAPPA and IGFBP-4 were measured using ELISA kits. The control group consisted of 19 non-obese, healthy children with correct body mass index and without organic pathologies.
Results:
The concentration of examined biomarkers in obese children with liver steatosis was significantly higher than in the control group and STC-2 was also significantly higher in children with advanced steatosis in comparison to children with mild steatosis. In the group of obese children with liver steatosis STC-2 positively correlated with: gamma-glutamyltransferase, cholesterol, triglycerides, low-density lipoprotein cholesterol, homeostatic model assessment-insulin resistance and waist-hip ratio. The ability of serum STC-2 to detect advanced liver steatosis was significant (AUC = 0.746, p = 0.0022, cut-off 135.27 pg/ml).
Conclusions:
This preliminary study demonstrated that STC-2 can be regarded as a potential non-invasive marker of advanced liver steatosis in obese children. The other analyzed parameters (PAPP-A and IGFBP-4) seem not to be useful in diagnosis of liver steatosis in obese children.
With the increasing prevalence of liver steatosis, non-invasive methods are sought to detect it and to assess the degree of lipid accumulation in the liver. The aim of this preliminary study was to assess the serum concentrations of stanniocalcin-2 (STC-2), pregnancy-associated plasma protein A (PAPP-A) and insulin-like growth factor binding protein (IGFBP-4) among children with obesity, check if they detect liver steatosis and determine whether they differentiate mild and advanced steatosis.
Material and methods:
This prospective study involved 62 obese children (39 boys and 23 girls, median age 13.75 years). Infectious, autoimmune, metabolic and toxic liver conditions were excluded. All subjects underwent body composition analysis, anthropometric measurements, abdominal ultrasound and routine blood chemistry analyses. STC-2, PAPPA and IGFBP-4 were measured using ELISA kits. The control group consisted of 19 non-obese, healthy children with correct body mass index and without organic pathologies.
Results:
The concentration of examined biomarkers in obese children with liver steatosis was significantly higher than in the control group and STC-2 was also significantly higher in children with advanced steatosis in comparison to children with mild steatosis. In the group of obese children with liver steatosis STC-2 positively correlated with: gamma-glutamyltransferase, cholesterol, triglycerides, low-density lipoprotein cholesterol, homeostatic model assessment-insulin resistance and waist-hip ratio. The ability of serum STC-2 to detect advanced liver steatosis was significant (AUC = 0.746, p = 0.0022, cut-off 135.27 pg/ml).
Conclusions:
This preliminary study demonstrated that STC-2 can be regarded as a potential non-invasive marker of advanced liver steatosis in obese children. The other analyzed parameters (PAPP-A and IGFBP-4) seem not to be useful in diagnosis of liver steatosis in obese children.
REFERENCES (27)
1.
Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood) 2018; 243: 213-221.
2.
Lebensztejn DM, Wierzbicka A, Socha P, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non- alcoholic fatty liver disease. Acta Biochim Pol 2011; 58: 563-566.
3.
Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztej D. Predictive role of interleukin-18 in liver steatosis in obese children. Can J Gastroenterol Hepatol 2018; ID 3870454.
4.
Bobrus-Chociej A, Wasilewska N, Harasim-Symbor E, et al. Lack of change in serum sCD36 concentration in children with non- alcoholic fatty liver disease – a preliminary study. Adv Med Sci 2021; 66: 35-40.
5.
Bobrus-Chociej A, Daniluk U, Flisiak-Jackiewicz M, et al. Estimation of gamma-glutamyl transferase as a suitable simple biomarker of the cardiovascular risk in children with non-alcoholic fatty liver disease. Acta Biochim Pol 2018; 65: 539-544.
6.
Flisiak-Jackiewicz M, Bobrus-Chociej A, Wasilewska N, et al. Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children? Adv Med Sci 2019; 64: 280-284.
7.
Hjortebjerg R. IGFBP-4 and PAPP-A in normal physiology and disease. Growth Horm IGF Res 2018; 41: 7-22.
8.
Joshi AD. New insights into physiological and pathophysiological functions of stanniocalcin 2. Front Endocrinol 2020; 11: 172.
9.
Parafati M, Kirby RJ, Khorasanizadeh S, Rastinejad F, Malany S. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. Dis Model Mech 2018; 11: dmm033530.
10.
Jepsen MR, Kloverpris S, Mikkelsen JH, et al. Stanniocalcin-2 inhibits mammalian growth by proteolytic inhibition of the insulin-like growth factor axis. J Biol Chem 2015; 290: 3430-3439.
11.
Steffensen LB, Conover CA, Bjorklund MM, Ledet T, Bentzon JF, Oxvig C. Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice. Atherosclerosis 2016; 248: 36-43.
12.
Fujimoto M, Hwa V, Dauber A. Novel modulators of the growth hormone – insulin-like growth factor axis: pregnancy-associated plasma protein-A2 and stanniocalcin-2. J Clin Res Pediatr Endocrinol 2017; 9: 1-8.
13.
Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol 2014; 28: 637-653.
14.
World Health Organization. Waist Circumference and Waist-Hip Ratio. Report of a WHO Expert Consultation. Geneva, 8–11 December 2008. WHO Press, World Health Organization 2011, Geneva, Switzerland. http://www.who.int/nutrition/p....
15.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. HOMA-IR and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985; 28: 412-419.
16.
Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J 1986; 292: 13-15.
17.
Zhao J, Jiao Y, Song Y, et al. Stanniocalcin 2 ameliorates hepatosteatosis through activation of STAT3 signaling. Front Physiol 2018; 9: 873.
18.
Yang S, Ji Q, Chang B, et al. STC-2 promotes head and neck squamous cel carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget 2017; 8: 5976-5991.
19.
Zhou J, Li Y, Yang I, et al. Stanniocalcin 2 improved osteoblastdifferentiation via phosphorylation of ERK. Mol Med Rep 2016; 14: 5653-5659.
20.
Jiao Y, Zhao J, Shi G, et al. Stanniocalcin 2 acts as an anorectic factor through activation of STAT3 pathway. Oncotarget 2017; 8: 91067-91075.
21.
Sookoian S, Castano G, Gianotti TF, Gemma C, Roselli MS, Pirola CJ. Genetic variants in STAT3 are associated with non-alcoholic fatty liver disease. Cytokine 2008; 44: 201-206.
22.
Panagiotou G, Anastasilakis AD, Kynigopoulos G, et al. Physiological parameters regulating levels of the IGFBP-4/STC-2/PAPPA axis. Metab Clin Exp 2017; 75: 16-24.
23.
Lake AD, Novak P, Hardwick RN, et al. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Toxicol Sci 2014; 137: 26-35.
24.
Pourteymour S, Eckardt K, Holen T. Global mRNA sequencing of human skeletal muscle: search for novel exercise-regulated myokines. Mol Metab 2017; 6: 352- 365.
25.
Lopez JJ, Jardin I, Chamorro CC, Duran ML. Involvement of stanniocalcins in the deregulation of glycaemia in obese mice and type 2 diabetec patients. J Clin Mol Med 2018; 22: 684-694.
26.
Ortega MA, Fraile-Martinez O, Asunsolo A, Martinez-Vivero C, Pekarek L. Chronic venous disease patients showed altered expression of IGF-1/PAPP-A/STC-2 axis in the vein wall. BioMed Res Int 2020; 2020: 6782659.
27.
Woelfle J, Roth C, Wunsch R, Reinehr T. Pregnancy-associated plasma protein A in obese children: relationship to markers and risk factors of atherosclerosis and members of the IGF system. Eur J Endocrin 2011; 165: 613-622.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
